医药生物行业资金流入榜 沪指9月30日上涨0.52%，申万所属行业中，今日上涨的有19个，涨幅居前的行业为有色金属、国防军 工，涨幅分别为3.22%、2.59%。医药生物行业今日上涨1.40%。跌幅居前的行业为通信、非银金融，跌 幅分别为1.83%、1.14%。 资金面上看，两市主力资金全天净流出323.03亿元，今日有4个行业主力资金净流入，国防军工行业主 力资金净流入规模居首，该行业今日上涨2.59%，全天净流入资金20.78亿元，其次是有色金属行业，日 涨幅为3.22%，净流入资金为19.84亿元。 主力资金净流出的行业有27个，非银金融行业主力资金净流出规模居首，全天净流出资金114.05亿元， 其次是通信行业，净流出资金为59.36亿元，净流出资金较多的还有机械设备、银行、电力设备等行 业。 医药生物行业今日上涨1.40%，全天主力资金净流入9.84亿元，该行业所属的个股共475只，今日上涨的 有310只，涨停的有2只；下跌的有145只，跌停的有2只。以资金流向数据进行统计，该行业资金净流入 的个股有198只，其中，净流入资金超亿元的有5只，净流入资金居首的是药明康德，今日净流入资金 11.13亿元 ...

截至9月29日收盘，维生素概念下跌0.18%，位居概念板块跌幅榜前列，板块内，*ST苏吴跌停，金城医 药、华恒生物、*ST中基等跌幅居前，股价上涨的有36只，涨幅居前的有吉林敖东、科源制药、海欣股 份等，分别上涨6.69%、1.93%、1.83%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 金属锌 | 3.68 | 猪肉 | -0.54 | | 金属镍 | 3.65 | 兵装重组概念 | -0.52 | | 金属铅 | 3.61 | 培育钻石 | -0.44 | | 期货概念 | 3.32 | 维生素 | -0.18 | | 钠离子电池 | 3.08 | 转基因 | -0.17 | | 金属钴 | 3.02 | 共享单车 | -0.14 | | 固态电池 | 2.96 | 乳业 | -0.12 | | 盐湖提锂 | 2.78 | 养鸡 | -0.12 | | PVDF概念 | 2.76 | 玉米 | -0.11 | | 钛白粉概念 | 2.73 | 宠物经济 | -0.11 | （文章来源：证券时报网） ...

主力资金净流出的行业有18个，电子行业主力资金净流出规模居首，全天净流出资金28.11亿元，其次 是国防军工行业，净流出资金为18.82亿元，净流出资金较多的还有医药生物、通信、传媒等行业。 医药生物行业今日上涨0.17%，全天主力资金净流出16.40亿元，该行业所属的个股共475只，今日上涨 的有285只；下跌的有169只，跌停的有2只。以资金流向数据进行统计，该行业资金净流入的个股有162 只，其中，净流入资金超5000万元的有8只，净流入资金居首的是吉林敖东，今日净流入资金1.06亿 元，紧随其后的是赛诺医疗、迈瑞医疗，净流入资金分别为1.01亿元、9185.92万元。医药生物行业资金 净流出个股中，资金净流出超5000万元的有8只，净流出资金居前的有恒瑞医药、广生堂、翰宇药业， 净流出资金分别为3.35亿元、1.60亿元、1.38亿元。（数据宝） 医药生物行业资金流入榜 沪指9月29日上涨0.90%，申万所属行业中，今日上涨的有26个，涨幅居前的行业为非银金融、有色金 属，涨幅分别为3.84%、3.78%。医药生物行业今日上涨0.17%。跌幅居前的行业为煤炭、银行，跌幅分 别为0.84%、0.46%。 ...

证券之星消息，9月29日中药板块较上一交易日上涨0.27%，吉林敖东领涨。当日上证指数报收于 3862.53，上涨0.9%。深证成指报收于13479.43，上涨2.05%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出2.44亿元，游资资金净流入3930.98万元，散户资金净 流入2.04亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000623 | 吉林敖东 | 9159.41万 | 9.58% | -6565.89万 | -6.87% | -2593.51万 | -2.71% | | 000538 云南白药 | | 2620.55万 | 5.49% | 264.90万 | 0.55% | -2885.45万 | -6.04% | | 603998 方盛制药 | | 1917.83万 | 8.65% | 383.21万 | 1.73% | -2301.0 ...

9月29日，吉林敖东涨5.23%，截至发稿，报20.12元/股，成交4.19亿元，换手率1.80%，总市值240.61亿 元。 资料显示，吉林敖东药业集团股份有限公司位于吉林省敦化市敖东大街2158号，成立日期1993年3月20 日，上市日期1996年10月28日，公司主营业务涉及中成药、生物化学药研发、制造和销售,同时积极布 局保健食品、食品、养殖、种植等领域。主营业务收入构成为：中药60.90%，连锁药店批发和零售 16.59%，化学药品12.73%，食品7.39%，其他产品1.76%，其他(补充)0.62%。 从基金十大重仓股角度 数据显示，南方基金旗下1只基金重仓吉林敖东。南方中证500增强策略ETF（560100）二季度持有股数 2.98万股，占基金净值比例为0.63%，位居第九大重仓股。根据测算，今日浮盈赚取约2.98万元。 南方中证500增强策略ETF（560100）成立日期2022年1月26日，最新规模8041.32万。今年以来收益 27.63%，同类排名1852/4221；近一年收益45.75%，同类排名1710/3836；成立以来收益21.77%。 南方中证500增强策略ETF（56010 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

Core Viewpoint - The recent surge in A-share market has attracted numerous investors, with listed companies increasingly engaging in securities investments, utilizing significant idle funds to capitalize on market opportunities [1][2]. Group 1: Company Investments - At least 8 companies have invested over 1 billion yuan in securities or fund management activities this year, with Liou Co. leading at 3 billion yuan, followed by Fangda Carbon and Seven Wolves at 2.4 billion yuan and 2 billion yuan respectively [1]. - Seven Wolves reported a net profit of 160 million yuan in the first half of 2025, with 130 million yuan derived from stock investments, despite its main apparel business generating only 30 million yuan [2]. - Liou Co. achieved a net profit of 478 million yuan in the first half of 2025, largely due to gains from its investment in Li Auto, which increased its market value significantly since its initial investment of 350 million yuan in 2016 [3]. Group 2: Market Performance - As of September 10, the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index have risen by 11.33%, 21.00%, and 36.71% respectively, with the Shanghai Composite Index surpassing the significant 3,800-point mark [1]. - Jin Feng Investment, a subsidiary of Jin Feng Technology, has been actively reducing its holdings in the rapidly appreciating stock of Shangwei New Materials, with estimated cash proceeds exceeding 100 million yuan from recent sales [4]. Group 3: Financial Strategies - Companies like Jiangsu Guotai have announced plans to utilize idle funds for financial management and securities investments, with a total planned investment of 12 billion yuan, although they faced criticism from investors leading to a cancellation of part of the plan [6][7]. - Jilin Aodong reported a net profit of 1.28 billion yuan in the first half of 2025, significantly exceeding its revenue of 1.13 billion yuan, primarily due to substantial financial asset investments [5]. - Companies are increasingly using idle funds for securities investments as a strategy to supplement their financial performance when core business growth is stagnant, reflecting a common practice in the current market environment [14].

Group 1 - Huadian Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] - Cisco Ray's 2022 annual report was found to have inflated revenue by 9.96 million and profit by 7.0054 million, leading to penalties and a change in stock name to ST Cisco Ray [3] - Tianpu Co., Ltd. experienced a 245.20% increase in stock price over 13 consecutive trading days, indicating a risk of rapid decline [4] - ST New Power is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6] - Baoli International intends to invest in semiconductor testing equipment company Hongtai Technology, acquiring 1%-3% equity [7] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Shiqi Future, focusing on smart vision technology [8] Group 2 - SF Holding reported a revenue of 24.787 billion yuan in August, a year-on-year increase of 7.86% [9] - Various companies are involved in share transfers, including Guangli Micro and *ST Tianlong, with plans for significant asset restructuring [11] - Xinwangda's subsidiary aims to establish a storage industry fund with professional investment institutions [12] - Several companies are planning share repurchases, including Shunhao Co. and Lingyun Optics, with adjustments to repurchase plans [18]

吉林敖东药业集团股份有限公司章程 吉林敖东药业集团股份有限公司 章 程 （经 2025 年 9 月 19 日召开的 2025 年第一次临时股东大会审议通过） 2025 年 9 月 1 | 第一章 | 总则 | | 3 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | | 4 | | 第三章 | 股份 | | 4 | | 第一节 | 股份发行 | | 4 | | 第二节 | | 股份增减和回购 | 5 | | 第三节 | 股份转让 | | 6 | | 第四章 | 股东和股东会 | | 7 | | 第一节 | | 股东的一般规定 | 7 | | 第二节 | | 控股股东和实际控制人 | 9 | | 第三节 | | 股东会的一般规定 | 10 | | 第四节 | | 股东会的召集 | 12 | | 第五节 | | 股东会的提案与通知 | 14 | | 第六节 | | 股东会的召开 | 15 | | 第七节 | | 股东会的表决和决议 | 18 | | 第五章 | 董事和董事会 | | 23 | | 第一节 | | 董事的一般规定 | 23 | | 第二节 | 董事会 | | ...

证券代码:000623 证券简称:吉林敖东 公告编号:2025-053 吉林敖东药业集团股份有限公司 关于控股子公司获得药品注册证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东洮南药业股份有限公司（以下简称"洮南药业"）收到国家药品监督管理 局下发的"升陷汤颗粒"的《药品注册证书》。现就相关情况公告如下： 一、《药品注册证书》的主要内容 药品通用名称：升陷汤颗粒 主要成份：黄芪、柴胡、升麻、知母、桔梗 剂型：颗粒剂 规格：每袋相当于饮片16.17g 注册分类：中药3.1类 药品注册标准编号：YBZ00642025 药品有效期：24个月 包装规格：聚酯/铝/聚乙烯药品包装用复合膜。每袋装10g，每盒装6袋、12 袋。 处方药/非处方药：处方药 受理号：CXZS2400020 证书编号：2025S02899 上市许可持有人名称：吉林敖东洮南药业股份有限公司 上市许可持有人地址：吉林省洮南经济开发区兴业路2999号 生产企业名称：吉林敖东洮南药业股份有限公司 生产企业 ...